BioXcel Therapeutics Inc

-0.31 (-2.08%)

Bioxcel Therapeutics Announces NIH NIDA Grant To Columbia University To Support Further Studies Of BXCL501

Published: 08/01/2022 12:07 GMT
BioXcel Therapeutics Inc (BTAI) - Bioxcel Therapeutics Announces Nih Nida Grant to Columbia University to Support Further Studies of Bxcl501 (sublingual Dexmedetomidine) for Treating Opioid Withdrawal.
Bioxcel Therapeutics - Multi-year-funded Award to Support 160-patient, Randomized-controlled Study in Patients Undergoing Opioid Withdrawal Treatment.
Bioxcel Therapeutics Inc - Initial Grant Provides Approximately $3.3 Million for Project From August 1, 2022 Through July 31, 2024.
Bioxcel Therapeutics Inc - Grant Includes Approximately $4.5 Million to Support a Registrational Study Upon Completion of Certain Milestones.
Bioxcel Therapeutics Inc - Grant to Support 4-arm Phase 2b Study Comparing Bxcl501 180 Mcg and 240 Mcg Bid to Placebo and Lucemyra.